Effector Therapeutics Inc
$ 0.00
-66.67%
17 Apr - close price
- Market Cap 940 USD
- Current Price $ 0.00
- High / Low $ 0.00 / 0.00
- Stock P/E N/A
- Book Value 0.21
- EPS -12.57
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.83 %
- ROE -9.47 %
- 52 Week High 0.00
- 52 Week Low 0.00
About
Effector Therapeutics Inc (EFTR) is a clinical-stage biopharmaceutical company focused on pioneering targeted cancer therapies through the selective modulation of RNA translation. By innovatively altering protein synthesis within tumor cells, the company aims to address significant unmet needs in oncology with its portfolio of small molecule treatments. With a diverse pipeline of product candidates under development, Effector Therapeutics is committed to advancing precision medicine, striving to enhance treatment outcomes and quality of life for cancer patients in a rapidly evolving biotechnology environment.
Analyst Target Price
$10.00
Quarterly Earnings
| Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2024-05-09 | 2024-03-25 | 2023-11-13 | 2023-08-08 | 2023-05-09 | 2023-03-08 | 2022-11-07 | 2022-08-09 | 2022-05-10 | 2022-03-16 | 2021-11-08 | 2021-08-31 |
| Reported EPS | -2.16 | -3.42 | -0.13 | -0.17 | -0.24 | -0.22 | -0.23 | -0.17 | 0.07 | 0.44 | 0.42 | -0.37 |
| Estimated EPS | -2.16 | -1.65 | -0.12 | -0.2 | -0.14 | -0.24 | -0.21 | -0.16 | -0.24 | -0.24 | -0.2 | -0.285 |
| Surprise | 0 | -1.77 | -0.01 | 0.03 | -0.1 | 0.02 | -0.02 | -0.01 | 0.31 | 0.68 | 0.62 | -0.085 |
| Surprise Percentage | 0% | -107.2727% | -8.3333% | 15% | -71.4286% | 8.3333% | -9.5238% | -6.25% | 129.1667% | 283.3333% | 310% | -29.8246% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EFTR
2026-03-30 08:41:09
This article provides an overview of eFFECTOR Therapeutics, Inc. (EFTR) stock, including its current price, market capitalization, performance, and key financials. It details the company's focus on developing selective translation regulator inhibitors (STRIs) for oncology and addresses frequently asked questions regarding its stock behavior and investment potential.
2026-03-17 18:09:11
This page provides a collection of recent news and events related to eFFECTOR Therapeutics (EFTR) stock. Key headlines indicate a significant drop in share price due to a failed NSCLC study and the company's decision to wind down operations, leading to an expected delisting of its securities. The latest news is predominantly negative, highlighting the company's struggles.
2026-03-01 05:51:29
This article provides the CapEx per share for eFFECTOR Therapeutics Inc (MUN:LWK) as listed on the Munich Stock Exchange. It highlights the financial metric and includes basic market information for the company. The page appears to be a financial data snippet from TradingView.
2026-02-24 16:51:43
This article provides an in-depth financial analysis of Effector Therapeutics Inc (EFTR), covering its income statement, balance sheet, and cash flow for fiscal years 2020-2023 and recent quarters. It highlights significant financial challenges including zero revenue in FY2023, negative net income, a weak Piotroski F-Score, low earnings quality, and concerns regarding liquidity and interest coverage. The company also has a calculated cash runway of approximately 6 months based on its operating cash burn.
2024-07-08 13:39:44
This article provides an overview of Effector Therapeutics (PNK:EFTR) stock, including its current share price, financial performance, and analyst forecasts. It details the company's profile as a clinical-stage biopharmaceutical company developing oncology drugs and lists key financial metrics, director information, and share price performance data. The stock is currently classified as "Highly Speculative Micro Cap" due to its financial state and its share price history.
2024-06-24 07:21:00
eFFECTOR Therapeutics (EFTR) has decided to terminate its employees and wind down all operations, including exploring strategic alternatives for its development programs. The company also plans to voluntarily request the delisting of its securities. Craig Jalbert has been appointed CEO, President, Treasurer, Secretary, and sole board member, as shares dropped 65% in pre-market trading.
